|
24102
Tsujino T, Yamazaki S, Sakamoto M, Yoshikawa Y, Maenosono R, Nakajima Y, Hirosuna K, Takai T, Nishimura K, Ishida M, Nakamura K, Iwatsuki K, Tsuchida S, Matsuda T, Higashio T, Fukushima T, Nishio K, Nakamori K, Tsutsumi T, Matsunaga T, Taniguchi K, Shimbo T, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Yamamoto K, Nihei K, Osuga K, Jia L, Kibel AS, Komura K, Yoshimi A, Azuma H.
A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
Signal Transduct Target Ther
2026
11(1)
PubMed ID: 42469227
DOI: 10.1038/s41392-026-02847-6
|
|
21489
Myoen S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Shindo N, Yamaguchi K, Yasuda J, Abe J, Imai T, Sato I, Adachi H, Kawamura S, Ito A, Tamai K.
CD271 promotes proliferation and migration in bladder cancer.
Genes Cells
2023
PubMed ID: 38016691
DOI: 10.1111/gtc.13087
|
|
14224
Aya Kikuchi, Tomoyuki Suzuki, Taisuke Nakazawa, Masateru Iizuka, Ayako Nakayama, Tohru Ozawa, Minoru Kameda, Nobuaki Shindoh, Tadashi Terasaka, Masaaki Hirano, Sadao Kuromitsu
ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance
Cancer Science
2017
108:236-242
PubMed ID: 27885740
DOI: 10.1111/cas.13124
|